Grants for Independent school districts - Food and Nutrition

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

The Avery Community Foundation (ACF) is offering community grants to qualified charitable organizations serving Avery County, North Carolina. This grant program aligns with the foundation's mission to address a broad range of local needs. The ACF seeks to support initiatives that strengthen the community across various sectors, demonstrating a strategic commitment to comprehensive local development. The grant program targets a diverse range of beneficiaries within Avery County, including those in need of human services, education, youth development, health, food/nutrition, and arts. The impact goal is to meet these local needs through funding programs that deliver direct benefits to the community-at-large. The foundation prioritizes organizations that provide programs and services without discrimination based on age, race, national origin, ethnicity, gender, physical ability, sexual orientation, political affiliation, or religious belief. The program focuses on supporting 501(c)(3) public charity nonprofit organizations, organizations with a fiscal agent who is a 501(c)(3) public charity, local governments (including public schools), and fire and rescue departments. Religious entities may also apply for funding to support social outreach and charitable service programs that benefit the community-at-large, but not for general operating support. This focus ensures that funding reaches a wide array of entities capable of implementing effective community programs. While specific measurable results are not explicitly detailed beyond meeting local needs, the foundation expects outcomes that demonstrably improve the quality of life and address the identified challenges within Avery County. The typical grant range of $500 to $1,000 suggests a strategy of providing smaller, impactful grants to support numerous local initiatives. The ACF's theory of change appears to be rooted in empowering local organizations to directly address community needs, thereby fostering a more resilient and thriving local environment.

INTEGRIS Health is offering a grant for programs in specified Oklahoma counties that align with their community health priorities, such as improving access to care, mental health care, obesity prevention, chronic disease management, access to healthy food, and tobacco use prevention, open to 501(c)(3) nonprofits and nonexempt organizations like schools and local government agencies.

This funding opportunity supports predoctoral students in dual-degree programs at institutions without NIH-funded training programs, helping them pursue research and clinical training to become future physician-scientists.

This funding opportunity supports the development of innovative tools and technologies aimed at advancing research and treatment in kidney, urologic, and hematologic diseases, encouraging projects that push scientific boundaries and have broad applications beyond individual research interests.

Summer Meal Program Expansion Grant Applications for the new Summer Meal Program Expansion Grant program are now open through May 7! Program Overview: The Iowa Department of Education has received $900,000 to support the enhancement and expansion of summer meal programs in currently underserved and eligible areas. Program Details: Funding Source: $900,000 from the U.S. Department of Agriculture (USDA) Purpose: Enhance and expand summer meal programs in underserved areas. Target Audience: Iowa children ages 18 and under. Programs Supported: Summer Food Service Program (SFSP) and Seamless Summer Option (SSO). Grant Opportunity: Provides additional revenue source for summer meal programs beyond federal meal reimbursement. Allowable Expenses: Enhancing meal quality, incorporating locally grown foods, updating program equipment, conducting program outreach, and operational/administrative personnel expenses not fully covered through meal reimbursement. Eligible Sites for Expansion: Possible new meal site locations include: Schools Community buildings Libraries Apartment complexes Parks Swimming pools Splash pads Churches Other public sites where children gather Non-Congregate Distribution: Non-congregate distribution may be an option for State agency approved sponsors in rural areas unserved by a congregate meal service. Application Deadline: May 7 Don't miss this opportunity to expand summer meal programs and ensure Iowa children have access to healthy meals during the summer break! Apply now!

This program provides funding to businesses, nonprofits, institutions, and school districts in Alameda County to replace single-use transport packaging with durable, reusable alternatives, helping to reduce waste and lower costs.

This grant provides funding to school districts and educational organizations to help start or expand meal programs that ensure children have access to nutritious breakfasts and summer meals.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

The Shullsburg Fund, established in 2004 by area citizens, serves as a permanent funding source dedicated to enhancing the quality of life in and around Shullsburg. Managed as a component of the Community Foundation of Southern Wisconsin, it annually redistributes a portion of its earnings to finance projects and programs that positively impact community life. The fund focuses on supporting non-profit organizations, the local school district, and local government agencies with charitable initiatives. Grants are ceremoniously awarded in June each year, underlining the fund's commitment to community development and welfare. Grant renewed every year. Grant annual deadline: May 15th

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEIs or ARBs/statin/aspirin and influenza/pneumonia vaccines).

This funding opportunity supports high-risk, multi-center observational studies aimed at improving understanding and treatment of diabetes, digestive diseases, and kidney-related conditions, targeting a wide range of eligible public and private institutions.

This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources , (3) implement a multipronged approach to support and grow the early-to-midcareer research workforce, including individuals from diverse backgrounds, with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program.This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This funding opportunity provides financial support to research institutions for developing and sharing essential resources to advance the study of Polycystic Kidney Disease, fostering collaboration and innovation in the field.

The Silvio O. Conte Digestive Diseases Research Core Centers grant, provided by the NIDDK, supports collaborative research on digestive and liver diseases by offering shared resources to enhance productivity and foster new ideas, centered around a theme within the NIDDK's mission.

This funding opportunity supports research projects aimed at reducing stigma related to HIV/AIDS in low- and middle-income countries, with a focus on improving health outcomes for affected populations.

Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.